Why Is Bristol Myers Squibb Stock Gaining Monday?
Bristol Myers Squibb stock jumped over 4% after positive Phase 3 results for neuroendocrine tumors and pulmonary fibrosis treatments.
Share
Why It Matters
Bristol Myers Squibb's new medicines passed important safety tests. When drug makers show their medicines work, people feel more hopeful about the company.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.